TrialThe oncologist2024

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.

Emeric Boisteau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.